Checkpoint inhibitors are available to a large share of cancer patients and work in a small one.

The most generous US estimate put 43.6% eligible and 12.5% responding;1 a European analysis put the benefit closer to one patient in twenty.2

Macrophages outnumber T cells in most solid tumors. Teaching them to eat is the half of immunotherapy nobody has finished.

Please note: Bexora Biotech operates in a stealth capacity.

This goes to the founding team, not to a list. We keep your details for correspondence and no other purpose. Your data.